文献速递免疫规划传染病防控与疫情报告

拉沙病毒常规与脉冲疫苗接种可降低地方性高发病负担:数学建模研究

Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study.
PubMed 文献 · Vaccine · 2019-05-11

本研究用确定性数学模型模拟拉沙病毒在啮齿动物与人间季节性传播,评估常规婴儿接种与全人群脉冲接种的效果。结果显示,婴儿接种覆盖40%、疫苗效力70%可使传染性病例减少30%,覆盖60%、效力90%可减少56%;每10年一次的全人群脉冲接种以11%覆盖(效力70%)即可减少30%,23%覆盖(效力90%)减少56%,且脉冲接种受免疫力持续时间影响较小。

要点

  • 婴儿常规接种覆盖40%、效力70%可使传染性病例减少30%,覆盖60%、效力90%可减少56%。
  • 每10年一次全人群脉冲接种覆盖11%、效力70%可减少30%,覆盖23%、效力90%可减少56%。
  • 脉冲接种对免疫力持续10–30年的影响仅略减,婴儿接种结论对免疫终身假设敏感。

核心结论

  • 有效的拉沙病毒疫苗接种规划应在常规儿童免疫基础上纳入脉冲接种,以限制疾病传播。
  • 需估算可行的疫苗覆盖率和效力,才能充分量化地方性流行区接种规划的预期收益。

研究设计与样本

  • 采用确定性数学模型,刻画啮齿动物与人间拉沙病毒季节性传播,评估常规与脉冲接种策略。

主要发现

  • 婴儿接种覆盖40%、效力70%时,传染性病例数减少30%;覆盖60%、效力90%时减少56%。
  • 全人群脉冲接种覆盖11%、效力70%时减少30%;覆盖23%、效力90%时减少56%,每10年重复一次。
  • 脉冲接种在降低频率但提高覆盖率时,传染性病例减少幅度更大。
  • 婴儿接种结论对免疫终身假设敏感,脉冲接种在免疫力持续10–30年时效果仅略减。

临床怎么用

  • 地方性流行区可考虑将脉冲接种与常规儿童免疫结合,以更快降低传染性病例数。
  • 规划接种策略时需结合当地可行的疫苗覆盖率和效力估算预期效果。

局限性

  • 婴儿接种效果结论依赖于免疫终身假设。
  • 需 feasible 疫苗覆盖率和效力估算才能充分量化接种规划的预期收益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lassa fever is an acute viral illness caused by Lassa virus (LASV), a rodent-borne pathogen. LASV is endemic to much of Sub-Saharan West Africa, where seasonal outbreaks cause significant morbidity and mortality. Increased global awareness of LASV has led to development of improved diagnostic tests, treatments and vaccines. As vaccine candidates are trialled, it is essential to assess the potential outcomes of introducing a LASV vaccination program in endemic regions. This study investigates the potential outcomes of routine and pulse vaccination strategies using a deterministic mathematical model that captures seasonal LASV transmission between rodents and humans. For plausible parameter values, we find that immunization of 40% of infants at 70% vaccine effectiveness achieves a population-level reduction in infectious case numbers of 30%, while coverage of 60% at 90% vaccine effectiveness achieves a 56% reduction. Similar reductions can be achieved more rapidly via population-wide pulse vaccination at 11% coverage (30% reduction at 70% effectiveness) or 23% coverage (56% reduction at 90% effectiveness) repeated every 10 years. Similar pulse vaccine doses delivered at reduced frequency, but increased coverage achieves a greater reduction in infectious cases. Findings around infant vaccination are sensitive to our assumption that immunity is life-long, while pulse-vaccination has only slightly reduced effect if immunity lasts 10-30 years. An effective LASV vaccination program would incorporate pulse vaccination in addition to routine childhood immunization to limit disease. Estimates of feasible vaccine coverage and effectiveness are needed to fully quantify the likely benefits of a vaccination program in LASV endemic regions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Davies J, Lokuge K, Glass K, et al. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study. Vaccine. 2019. PMID: 31088745. doi:10.1016/j.vaccine.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。